In melanoma, prostate cancer, hepatocellular cancer and colon cancer, EZH2-induced epigenetic marks inhibit Th1 polarization and IFN-γ-JAK-STAT signaling, with EZH2 knockdown or pharmacologic inhibition using DZNep or GSK126, restoring IFN-γ-induced gene expression (157–160). This evidence concerns the gene EZH2 and prostate cancer.